Optimal Duration Of Neoadjuvant Androgen Deprivation Therapy In Localised Prostate Cancer Treated By Radiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$422,335.00
Summary
The 96.01 trial aims to find out whether androgen deprivation (AD) administered prior to and during radiotherapy (i.e., neo-adjuvant AD) will improve outcomes in patients with locally advanced prostate cancer that is considered inoperable and is treated for cure by radiotherapy. The trial also aims to find out whether six months AD produces outcomes superior to those achieved by three months AD. The trial has been running since 1996 and involves 802 men who attend 19 cancer treatment centres acr ....The 96.01 trial aims to find out whether androgen deprivation (AD) administered prior to and during radiotherapy (i.e., neo-adjuvant AD) will improve outcomes in patients with locally advanced prostate cancer that is considered inoperable and is treated for cure by radiotherapy. The trial also aims to find out whether six months AD produces outcomes superior to those achieved by three months AD. The trial has been running since 1996 and involves 802 men who attend 19 cancer treatment centres across Australia and New Zealand. It would not have been possible without the continuous funding support of the NHMRC. So far this trial has shown that AD does prevent prostate cancer from returning after radiotherapy. This is very important because the need for treatment of recurrent cancer (usually AD for the rest of the patient's life) is halved by 6 months AD compared to standard treatment (radiotherapy alone). However, it is now necessary to observe the patients in this trial for another 5 years to find out whether AD also prolongs life, and whether 6 months AD is more effective than 3 months. Further patient follow up is also necessary to identify whether some men respond better to treatment than others. This is very important because it will enable treatment to be tailored to individual patients, in particular those who require more treatment than is given in this trial. This funding application is therefore to enable patient follow up on this large scale trial for another 5 years.Read moreRead less
Optimal Duration Of Neoadjuvant Androgen Deprivation Therapy In Localised Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$275,000.00
Summary
Each year approximately 8000 men in Australia and New Zealand develop prostate cancer which has not spread widely and which is amenable to attempted cure by surgery or radiation. Prostate cancer depends for its growth on the male hormone, testosterone, which circulates in the blood. As a result treatment which reduces testosterone level ('androgen deprivation' [AD] therapy) can produce shrinkage of prostate cancer. In fact AD has caused temporary but valued relief to millions of men with cancer ....Each year approximately 8000 men in Australia and New Zealand develop prostate cancer which has not spread widely and which is amenable to attempted cure by surgery or radiation. Prostate cancer depends for its growth on the male hormone, testosterone, which circulates in the blood. As a result treatment which reduces testosterone level ('androgen deprivation' [AD] therapy) can produce shrinkage of prostate cancer. In fact AD has caused temporary but valued relief to millions of men with cancer of the prostate that has spread throughout the body for the last five decades, worldwide. It remains uncertain however whether AD administered before surgery or radiation will benefit any of the 8000 men each year who develop localised cancer by shrinking the cancer first. In 1996 a trial involving 800 men across Australia and New Zealand commenced under the auspices of the Trans-Tasman Radiation Oncology Group (TROG) to answer the questions: 1 - Does either 3 or 6 months AD prior to radiotherapy reduce the chances of recurrence of the cancer after radiotherapy? 2 - Does such therapy reduce the volume of tissue requiring radiotherapy and hence the chances of long term side effects after radiotherapy? This grant will support collection of follow-up information from the trial and hence answers to the questions asked.Read moreRead less
Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Through this Australia Fellowship, Prof Keall and his tream will substantially improve the accuracy and effectiveness of radiation therapy for cancer by developing new techniques that will be able to ‘target’ a tumour in real-time and ‘concentrate fire’ on the most resistant and aggressive parts of it. Success in physiological targeting will create a paradigm shift in radiation therapy and could literally be a lifesaver. It’s a big challenge, but if this five-year research program succeeds, it w ....Through this Australia Fellowship, Prof Keall and his tream will substantially improve the accuracy and effectiveness of radiation therapy for cancer by developing new techniques that will be able to ‘target’ a tumour in real-time and ‘concentrate fire’ on the most resistant and aggressive parts of it. Success in physiological targeting will create a paradigm shift in radiation therapy and could literally be a lifesaver. It’s a big challenge, but if this five-year research program succeeds, it will pay big dividendsRead moreRead less
Improving Patient Safety In Radiation Therapy With The Watchdog Real-time Treatment Delivery Verification System
Funder
National Health and Medical Research Council
Funding Amount
$593,742.00
Summary
Radiation therapy is a highly effective cancer treatment with extremely high doses delivered using very complex treatment machines. Unfortunately errors have occurred resulting in cases of patient death and mistreatment. We have developed a novel method to assess the treatment delivery in real-time to prevent errors. The method uses imaging devices that are already present on the treatment machine meaning that this method could have a major impact on patient safety in modern radiation therapy.
Biofocussed Prostate Cancer RadioTherapy (BiRT): A Personalised Approach To Delivering The Right Dose To The Right Place
Funder
National Health and Medical Research Council
Funding Amount
$753,565.00
Summary
We propose a new approach to treating prostate cancer with radiotherapy to move from the standard whole prostate treatment to a personalised treatment that varies radiation intensity throughout the prostate. We will mathematically combine features that influence radiotherapy effect from advanced imaging, clinical and biopsy information. This model will map out the radiotherapy dose required at each part of the prostate, to maximise killing of the cancer whilst minimising harm to normal tissue
The Trans Tasman Radiation Oncology Group is an experienced research group conducting cancer clinical trials involving radiotherapy (RT) in order to improve cure rates, quality of life and to reduce side-effects of treatment. Fifty per cent of all cancer patients need RT as part of their treatment. The aim of the proposal is to strengthen the quality and safety of RT trials by (a) enabling rapid review and checking of treatment by electronic means and (b) improve trial design.
The Role Of Adjuvant Zoledronic Acid In Locally Advanced Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$384,132.00
Summary
This project seeks to confirm the highly encouraging early findings from the RADAR prostate cancer trial so that the new treatments tested can be brought in to clinical practice. The trial involved 1071 men at 23 cancer treatment centres in ANZ who had developed extensive cancerous masses in their prostates but without evidence of spread. All received their trial treatments between 2003 and 2007. This project involves the collection and analysis of follow up information up until September 2017.
New Copper and Rhenium Radiopharmaceuticals. The aims of this project are to provide new metal-based radiopharmaceuticals for the treatment of cancer, and the imaging of cancer and other conditions through the design and engineering of new coordination complexes of rhenium and copper. Various strategies will be used to selectively and specifically target these metal complexes to the desired areas in vivo for non-invasive imaging and therapeutic applications. The most promising candidates will be ....New Copper and Rhenium Radiopharmaceuticals. The aims of this project are to provide new metal-based radiopharmaceuticals for the treatment of cancer, and the imaging of cancer and other conditions through the design and engineering of new coordination complexes of rhenium and copper. Various strategies will be used to selectively and specifically target these metal complexes to the desired areas in vivo for non-invasive imaging and therapeutic applications. The most promising candidates will be tested in the appropriate cells.Read moreRead less